Fact: What management said in the letter

"Success of the Phase 2 trial (i) could be among the first or the first combination therapy to beat monotherapy CB, (ii) may delineate a viable regulatory pathway, (iii) may potentially catalyze a collaboration with a commercial pharmaceutical company that has an anti-PD-(L)1 drug, and/or (iv) potentially lead to an increase of the Company’s enterprise value that potentially may allow Provectus to raise investment capital at higher share prices."

Fiction: What Vorlon interprets

"I think first FDA acceptance of P2/3 melanoma stage III protocols. If FDA acceptance then PVCT initiates P2/3 melanoma protocols. Once approved, then perhaps a codevelopment deal is in play. Just one codevelopment deal? Well that just might be dumb. Once the FDA might allow further development…then why not NET or Uveal. "

If you know how to read you can understand what I am pointing here...this is just one of the many examples. Thats why I call them delusional posters.